Asia
Energenesis Gets US FDA's 'Clinical Hold Notice' for Parkinson's Disease Drug Clinical Trial; Shares Down 4%
Energenesis Biomedical's (TPE:6657) investigational new drug ENERGI-F705PD, an oral medication for Parkinson's disease, has received a "clinical hold notice" for its application to the US Food and Drug Administration (US FDA) for a Phase II clinical trial, according to a Monday filing to the Taiwan bourse.The company's shares were down nearly 4% in Tuesday's trade.The company said it will submit a revised response after receiving the complete notice of the US FDA's comments.
TPE:6657
